Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

Inclusion Criteria: * Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements. * Histologically confirmed and documented ovarian cancer with malignant ascites. * ECOG(Eastern Cooperative Oncology Group, ECOG) PS 0-2. * Life expectancy of \>3 months. * No serious inadequate bone marrow function, liver and renal function or significant cardiovascular disease. Exclusion Criteria: * Known hypersensitivity to any of the study drugs or excipients. * Any current anti-cancer therapy. * No evidence of ascites. * Key organ dysfunction. * Significant cardiovascular disease (e.g. congestive heart failure (CHF), uncontrolled cardiac arrhythmia, angina, heart valve disease, myocardial infarction and refractory hypertension need to be long time controlled by medicine). * Non-healing wound, ulcer or bone fracture. * Uncontrolled psychiatric history.